Avidity Biosciences (RNA)
(Real Time Quote from BATS)
$24.23 USD
-0.86 (-3.43%)
Updated Apr 25, 2024 01:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Avidity Biosciences, Inc. (RNA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$47.83 | $71.00 | $33.00 | 90.63% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Avidity Biosciences, Inc. comes to $47.83. The forecasts range from a low of $33.00 to a high of $71.00. The average price target represents an increase of 90.63% from the last closing price of $25.09.
Analyst Price Targets (6 )
Broker Rating
Avidity Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 85.71% and 14.29% of all recommendations. A month ago, Strong Buy made up 85.71%, while Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.14 | 1.17 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/11/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
3/14/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Not Available | Strong Buy |
3/5/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
11/9/2023 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
10/8/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 7 |
Average Target Price | $47.83 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -0.81 |